Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Read More
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
Clovis’ PARP inhibitor rucaparib will get a speedy review from US regulators as a treatment for patients with certain forms of advanced ovarian cancer.
Read More
